Month: May 2025

Alaris Equity Partners Income Trust Releases 2025 First Quarter Financial Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (TSX-AD.UN) (together, as applicable, with its subsidiaries, “Alaris” or the “Trust“) is pleased to announce its results for the three months ended March 31, 2025. The results are prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board. All amounts below are in Canadian dollars unless otherwise noted. Highlights:For the period ended March 31, 2025, Alaris generated $0.12 per unit of additional Net book value (1), improving this metric to $24.34. Driving this increase is current quarter earnings of $0.50 per unit, offset by $0.34 of...

BioSyent Schedules First Quarter Earnings Release for May 15, 2025

Written by Customer Service on May 8, 2025. Posted in Public Companies.

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation on the Company’s first quarter 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals...

Hepsiburada Announces First Quarter 2025 Financial Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

ISTANBUL, May 08, 2025 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), today announces its unaudited financial results for the first quarter ended March 31, 2025. Restatement of financial information: Pursuant to the International Accounting Standard 29, Financial Reporting in Hyperinflationary Economies (“IAS 29”), the financial statements of entities whose functional currency is that of a hyperinflationary economy must be adjusted for the effects of changes in a general price index. Turkish companies reporting under International Financial Reporting Standards (“IFRS”), including the Company, have been required to apply IAS 29 to their financial statements for periods ended on and after...

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate development of CTx-2103. “The first quarter of 2025 has been a very constructive one for Cingulate,” stated Chairman and CEO Shane...

Galecto Reports First Quarter 2025 Operating and Financial Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. “During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued preclinical studies to support our planned IND submission, which remains on track for Q1 2026. To date, preclinical data have shown significant improvement in efficacy compared to current FLT3 and menin inhibitors, with activity across a broad spectrum of patient genotypes. We believe GB3226 has the potential not only as a monotherapy but also as a powerful combination agent...

Montauk Renewables Announces First Quarter 2025 Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

PITTSBURGH, May 08, 2025 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights: • Revenues of $42.6 million, increased 9.8% compared to the first quarter of 2024 • Net loss of $0.5 million, compared to net income of $1.9 million for the first quarter of 2024 • Non-GAAP Adjusted EBITDA of $8.8 million, decreased 7.2% year-over-year • RNG production of 1.4 million MMBtu, flat compared to first quarter of 2024 • RINs sold of 9.9 million, increased 2.0 million or 25.3% year-over-year Our profitability is highly dependent on the market...

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Written by Customer Service on May 8, 2025. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail:Date: Tuesday, May 13, 2025Time: 8:30 a.m. ETWebcast Link: https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link: https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors...

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune status Conference call and webcast today at 5:00 PM Eastern TimeSAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided recent business updates. “Coinciding with the end of the 2024-2025 flu season in the Northern Hemisphere, we have established April 30,...

PacBio Announces First Quarter 2025 Financial Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024Revenue $37.2 million $38.8 millionInstrument revenue $11.0 million $19.0 millionConsumable revenue $20.1 million $16.0 millionService and other revenue $6.0 million $3.8 millionRevio™ systems 12 28Vega™ systems 28 —Annualized Revio pull-through per system ~$236,000 ~$254,000Cash, cash equivalents, and investments $343.1 million $561.9 millionGross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release. GAAP gross profit for the first quarter...

Clarus Reports First Quarter 2025 Results

Written by Customer Service on May 8, 2025. Posted in Earnings Releases And Operating Results.

Continues to Execute Strategic Initiatives to Accelerate Long-Term Profitable Growth Promotes Industry Veteran Tripp Wyckoff to Lead Adventure Entered into Agreement to Divest PIEPS Snow Safety Brand for €7.8 Million SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year‐Ago QuarterSales of $60.4 million compared to $69.3 million. Gross margin was 34.4% compared to 35.9%; adjusted gross margin of 34.6% compared to 36.9%. Net loss of $5.2 million, or $(0.14) per diluted share, compared to net income, which includes the impact of discontinued operations, of $21.9 million, or $0.57 per diluted...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals